

4 DECEMBER 2025

PACIFIC EDGE NAMES SIMON FLOOD CHAIRMAN DESIGNATE

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces the appointment of Mr Simon Flood as a Director and Chairman Designate.

Mr Flood is to replace Chris Gallaher who in September 2024 — at the invitation of Pacific Edge Directors — delayed his retirement until a successor was appointed. Mr Flood will join the Board today and will assume the role of Chairman at the conclusion of the next Board meeting on 18 December 2025.

Mr Flood brings a wealth of experience in business leadership and a global perspective on capital markets and investment management. He has held senior investment management and leadership roles in London, Hong Kong and Singapore with Mercury Asset Management, Axa Investment Management, Lion Global Investors and Merrill Lynch Investment Managers. He has also worked as an Executive Director at UK-based, technology-focused venture capital firm Imprimatur Capital.

Since returning to New Zealand in 2015, he has been appointed to several governance positions across a variety of sectors. He is currently Chairman of Queenstown Airport, a recent appointee to the Tertiary Education Commission, and several South Island organisations.

Pacific Edge Chair Chris Gallaher said: “We are delighted Simon has agreed to join the Board and take on the Chairman role. With Pacific Edge now in the strongest position yet to regain Medicare reimbursement of Cxbladder in the US, Simon’s deep understanding of capital markets and how to scale innovative technology businesses will be of enormous value to the company.

“I am meanwhile looking forward to my, long-delayed retirement. My confidence in the future of the company remains strong. I am delighted to be leaving the Board leadership of Pacific Edge in such capable hands and look forward to following, and as a shareholder sharing in, the company’s success.”

Mr Flood said: “I am looking forward to joining the Board and stepping into the Chairman role at the conclusion of the December Board meeting. Pacific Edge is the first mover and market leader in bladder cancer diagnostics offering clinical utility, patient satisfaction and economic value to healthcare payers around the world. This proposition is backed by the highest quality evidence and an ongoing robust evidence generation program that will entrench its leadership.

“The immediate challenge before the company is to overcome the restrictive decisions on Medicare coverage of Cxbladder. However, I share the Board’s view that with the landmark inclusion of Cxbladder Triage in the 2025 revision to the American Urological Association’s Microhematuria Guideline, that clinical and healthcare payer policy maker opinion is now turning in the company’s favor. This paves the way for a return to growth, and I am looking forward to working with my fellow Directors, Chief Executive Dr Peter Meintjes and his team through this next phase.”

Pacific Edge Independent Director Bryan Williams thanked Mr Gallaher for the support and leadership of the company through what has been one of the most challenging periods in the company's history.

"Chris has over the last two years put the interests of Pacific Edge and its shareholders above his own, providing stability and confidence to its stakeholders amid the continued uncertainty over the Medicare coverage status for the company's tests.

"With the appointment of Simon, and our Medicare Administrative Contractor Novitas convening an expert panel in February 2026 to consider the evidence and clinical opinion supporting the use of our tests, typically a step that precedes the opening of a new or substantially revised Medicare coverage determination, Chris leaves the company in a strong position. The Board, on behalf of shareholders, thanks him for his leadership of the company over the last nine years."

Investors:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: 022 032 1263

Media:

Richard Inder
The Project
P: +64 21 645 643

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.

